The cysteine protease cathepsin B acts as a key player in apoptosis. Cathepsin B mediated cell death is induced by various stimuli such as ischemia, bile acids or TNFα. Whether cathepsin B can be influenced by anticancer drugs, however, has not been studied in detail.
Introduction
Most anticancer drugs trigger cell death through apoptosis or activate a program leading to growth arrest. The underlying molecular pathways have been thoroughly characterized for several substances. Among them, cathepsin B has been of particular interest. In fact, Cathepsin B is a crucial component in different models of apoptosis including neuronal apoptosis [1] , or bile acid-induced hepatocyte apoptosis [2] . Furthermore, hepatocytes from cathepsin B knockout mice are resistant to TNFα-induced apoptosis [3] . Similarly, TRAILinduced apoptosis of oral cancer cells is also mediated by cathepsin B [4] and induction of this protease upon 1,25-dihydroxy vitamin D(3) is accompanied by sensibilization of tumor cells against TNFα [5] . Furthermore, inhibition of cathepsin B significantly reduces hepatocyte apoptosis and liver injury in cholestasis [6] or TNFα-induced acute liver failure [3] . Finally, cathepsin B expression is significantly elevated in various types of cancer [7] suggesting this protease as a suitable drug target. However, the role of this cysteine protease for cell death induced by anticancer drugs has not been addressed in detail. Recent evidence using pharmacological inhibition of cathepsin B points to a role of this protease in proteasome inhibitor PS-341 (bortezomib) [8] and paclitaxel induced cell death [9] but only slightly in camptothecin mediated apoptosis [10] suggesting a stimuli dependent involvement of cathepsin B.
Testing a variety of anticancer drugs, we could recently demonstrate a selective regulation of cathepsin B expression and activity by doxorubicin suggesting that this protease could be involved in doxorubicin mediated cell death [11] . Doxorubicin is one of the most important anticancer drugs used in a wide variety of malignancies including breast cancer, cervix carcinoma or lymphoma [12;13] . Despite its longstanding clinical use, the antiproliferative and death-inducing action of doxorubicin remains controversially discussed. Proposed modes of action involve intercalation into DNA, inhibition of topoisomerase II, free radical generation and damage of cell membrane permeability and fluidity [14] triggering tumor cell death [15] in which caspases are considered to be major executioners. Blocking Caspase activation did not prevent cell killing in leukemic blast cells and neuroblastoma cells induced by chemotherapeutics including doxorubicin [16;17] . Additionally, doxorubicin induced death in neuroblastoma cells is also Caspase-independent [18] and Caspase inhibition switches doxorubicin induced apoptosis to senescence [17] . These data strongly suggest that additional factors play a pivotal role in cell death.
In this paper, we identify a significant contribution of cathepsin B to doxorubicin induced cell death and characterized the molecular mechanisms. Using siRNA technology we demonstrate reduced Caspase 3 activation and PARP cleavage, decreased loss of mitochondrial membrane permeabilization and release of cytochrome C and AIF into cytosol in doxorubicin-treated cathepsin B silenced cells. Distinct regulation of apoptotic and cell cycle regulatory proteins in cathepsin B suppressed cells was accompanied by a reduction in subG 1 fraction. A lack of significant changes in the other cell cycle phases, however, may be indicative of additional cell cycle independent actions of the regulated proteins.
In summary, our data provide evidence for cathepsin B dependent modulation of doxorubicin induced cell death.
Materials and Methods

Materials
Doxorubicin hydrochloride (Sigma Aldrich, Deisenhofen, Germany) stock solutions were prepared in dimethyl sulfoxide (DMSO). Trypsin, RPMI1640 and DMEM were from PAN (Aidenbach, Germany). FCS and Lysotracker Red were obtained from Invitrogen (Karlsruhe, Germany). The cathepsin B specific inhibitor CA-074Me, the cathepsin B substrate Z-AMC and propidium iodide were from Sigma Aldrich (Deisenhofen, Germany).
Cell Lines, Culture Conditions and Retroviral Infection
HeLa cells were cultured in RPMI1640 supplemented with 10% FCS, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin at 37°C under 5% CO 2 .
Further cell lines used for this study were the glioma cell lines U87MG and LN18, the hepatoma cell line HepG2, the pancreatic adenocarcinoma cell line PaTuO2, the colon carcinoma cell line Caco2 (all cell lines were obtained from ATCC, Manassas, VA, USA).
Additionally, we tested a panel of parental doxorubicin-sensitive and doxorubicin-resistant cell lines. The neuroblastoma cell line UKF-NB-3 was established from bone marrow metastasis of an own patient (Kotchetkov et al., 2005) . IMR-32 neuroblastoma cells and H9 lymphoma cells were obtained from ATCC (Manassass, VA, USA). The rhabdomyosarcoma cell line HA-OH1 was kindly provided by Dr. Koscielniak (Olgahospital Stuttgart, Germany). The Ewing's sarcoma cell line MHH-ES-1, the osteosarcoma cell line SAOS-2, and the bladder cancer cell line TCC-SUP were received from DSMZ (Braunschweig, Germany). The prostate cancer cell line DU145 was obtained from DKFZ (Heidelberg, Germany). Cells were adapted to growth in the presence of doxorubicin (DOX, obtained from medac Gesellschaft für klinische Spezialpräparate mbH, Hamburg, Germany) by described methods and named following the published nomenclature [19] TGTATCCGTAGTGCTTGTCGGGTT-3´. Annealing of the forward and reverse primer was performed using 3 µg of each oligonucleotide in 50 µl annealing buffer (100 mM NaCl, 50 mM HEPES, pH 7.4) Annealed siRNA was ligated into XhoI and Bsp119l digested retroviral vector pQCXIH (Clontech, Saint-Germain-en-Laye, France). Virus production was performed according to a standard protocol from clontech. For the inward transfer of the siRNA, HeLa cells were stably infected with empty (HeLa-Co) or cathepsin B siRNA encoding retrovirus (HeLa-Cat B-2). Stably transfected sublines were generated by hygromycin (Invitrogen, Karlsruhe, Germany) selection (0.2 mg/ml).
Quantitation of cathepsin B mRNA
Quantitation of cathepsin B expression was performed by real-time polymerase chain reaction (RT-PCR). Total RNA was isolated using peqGold RNAPure (peqlab, Erlangen, Germany) and reversely transcribed with TaqMan® Reverse Transcription Reagents according to the manufacturer´s instruction (Applied Biosystems, Weiterstadt, Germany). RT-PCR was performed with the ABI PRISM 7700 sequence detection system and was analyzed with the 1.7 software (Applied Biosystems, Weiterstadt, Germany). The cathepsin B cDNA fragment was amplified using the primers CatB-For 5'-TGGACAAGAA AAGGCCTGGTT-3' and CatB-Rev 5'-CCGTTGACG TGGTGCTCA-3'. The sequence of the 5-carboxyfluoresceinlabeled probe was 5'-CCCATGTAGGGTGCAGACCGTACTCC-3'. Amplification of the endogenous control was performed with the ribosomal 18S Taqman PCR master mix (Applied Biosystems, Weiterstadt, Germany). Gene expression was quantified using the threshold PCR cycle number (Ct) method (∆∆C T -method) .
Protein isolation and Western Blotting
Cells were lysed for 30 min on ice in 50 mM Tris-HCl, 100 mM NaCl, 0.1% Triton-X100 and 5 mM EDTA (pH 7.4) supplemented with protease inhibitors (1 mM PMSF, 1 mM leupeptin, 1 mM aprotinin and 250 µg/ml sodium vanadate) and centrifuged at 13,000 g for 5 min to remove cell debris. The amount of protein was determined by the BCA method using bovine serum albumine. 50 µg of protein were separated on a 12.5% SDS-PAGE and transferred to polyvinylidene fluoride membranes (Millipore). The following primary antibodies were used:
Technology, Frankfurt am Main, Germany), anti-XIAP (BD Biosciences) and antiglyceraldehyde-3-phosphate dehydrogenase (GAPDH, Biodesign Int., clone 6C5, Saco, Maine USA). Reactive bands were detected using enhanced chemiluminescence on X-ray films, normalized to GAPDH using Image Quant 5.0 software and shown as arbitrary units (AU).
Cathepsin activity assay
Enzyme activity of cathepsin B was determined using the specific fluorogenic substrate Z-AMC (Sigma Aldrich, Deisenhofen, Germany) as described previously [11] .
Caspase activity assays
Caspase 3, 8 and 9 activities were measured in cell lysates with commercially available
Colorimetric assay kits (R&D Systems, Wiesbaden, Germany) according to the manufacturer´s instructions, normalized to the respective protein content and are shown as xfold increase relative to DMSO control. 
Analysis of mitochondrial depolarization
Release of cytochrome C and AIF into cytosol
For determination of release of cytochrome C and AIF into cytosol, cells were harvested, centrifuged at 6000 rpm for 5 min and lysed by incubating in digitonin lysis buffer (80 mM KCl, 8 mM Na 2 HPO 4 , 1 mM NaH 2 PO 4 , 1 mM EDTA, and 0.02% digitonin) for 10 min at room temperature. The lysate was centrifuged at 1000xg for 10 min. The supernatant was collected and further centrifuged at 50.000xg for 1 h at 4°C. The resulting supernatant was considered as cytosolic fraction, was quantified by the BCA method and 30 µg protein were subjected to immunoblot analysis using anti-AIF (Cell Signaling Technology, Frankfurt am Main, Germany) and anti-cytochrome C (BD Pharmingen, Heidelberg, Germany).
Additionally, the purity of cytosolic fraction was determined using an antibody against a mitochondria-specific protein namely Antioxidant protein 1 (not shown).
Cell cycle analysis
Determination of cell cycle was performed using propidium iodide staining. Briefly, treated and untreated cells were harvested and pooled with the floating cells. After centrifugation at 3000 rpm for 5 min, cells were washed once with PBS and fixed in ethanol overnight at 4°C.
After fixation, cells were centrifuged at 4000 rpm for 2 min and washed two times with PBS.
Pellets were resuspended in 500 µl staining buffer (1% glucose, 2 mg/ml RNase A, 50 µg/ml propidium iodide) and incubated for 30 min at room temperature in the dark. Measurement of propidium iodide incorporation into DNA was analyzed by FACS at the FL-2 channel and the respective cell cycle phase was expressed as percentage of total cell population.
Cell viability assay
HeLa cells were seeded at 5,000 cells/well in a 96-well multiplate. The growth medium was changed after 1 day and replaced by DMSO or doxorubicin containing media. After the respective incubation period, 1/10 of Alamar Blue (BioSource/Invitrogen, Karlsruhe, Germany) was added and analysis was performed according to the manufacturer´s instruction.
Data were expressed as percentage of cell viability of DMSO treated control cells.
Statistical analysis
Data represent at least three independent experiments and were expressed as the mean±SD. M a n u s c r i p t Fig. 2A-Left) . In addition, pre-incubation with the cathepsin B inhibitor CA074Me also reduced doxorubicininduced Caspase 3 activity ( Fig. 2A-Right) . In contrast to Caspase 3, there was no significant difference in Caspase 8 and 9 activity level between control transfectants and cathepsin B suppressed cells (Fig. 2B+C) . respectively. In cathepsin B suppressed cells, intact mitochondrial membrane potential was also elevated from 57±3.78% upon doxorubicin alone to 70.3±3.13% and 71.1±4.08% by additional application of CA074Me and Z-DEVD-fmk, respectively, but these differences
were not so pronounced as in control transfected cells (Fig.3B ).
Having shown a major loss ∆Ψm upon doxorubicin, we next studied the release of cytochrome C and AIF into cytosol. For both cytochrome C and AIF, in cathepsin B silenced
HeLa cells the release was significantly reduced after doxorubicin treatment compared to control transfected cells. As shown in Figure 3C , cytochrome C release in control transfected cells upon doxorubicin treatment was induced to 1131±117% and 2302±792% compared to the untreated control and in cathepsin B silenced cells to only 345±125% and 569±292% after 48 and 72h, respectively. AIF release in control transfected cells was enhanced to 507±147%
and 2926±646% and in cathepsin B silenced cells only to 242±153% and 259±57% after 48 and 72h, respectively (Fig. 3D ).
Influence of cathepsin B suppression on regulation of members of the Bcl2 family, XIAP and p53
Apoptosis is accompanied by up-regulation of the pro-apoptotic Bcl-2 family member Bax, which is involved in the mitochondrial apoptosis pathway and Bcl-2 has been characterized as potent inhibitor of apoptosis and regulation of this anti-apoptotic protein by doxorubicin is known [21] . We therefore analyzed Bax and Bcl-2 expression in doxorubicin treated control transfectants and cathepsin B suppressed cells. As shown in In contrast to Bcl-2, protein levels of the anti-apoptotic Bcl -xL were significantly enhanced by doxorubicin treatment in both control transfectants (AU DMSO 0.32±0.14 and Dox (Fig. 4A/B ).
The anti-apoptotic action of Bcl-2 and Bcl-xL is inhibited by the Bcl-2 family member Bax. As demonstrated in Fig. 4A (Fig. 4A/B ).
Since it has been shown that doxorubicin induced p53 expression and can activate p53 dependent apoptosis [22] , we characterized expression of p53 in our cell model. As shown in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 In addition, at 48h after doxorubicin application no significant alteration in protein expression was seen for Bax, Bid, Bcl-2, Bcl-xL and p53 and a down-regulation for XIAP (data not shown).
Influence of cathepsin B suppression on cell cycle regulatory proteins
It has been described in detail in various tumor cell models that doxorubicin results in an arrest in the G 2 M phase [24] . The underlying modification of cell cycle regulatory proteins, however, has not been addressed in extenso. (Fig.5A/B) .
A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Another cdk1 regulator is the phosphatase cdc25 responsible for activation of cdk1 through its dephosphorylating activity [25] . As demonstrated in Fig. 5A (Fig 5A/B) .
Notable, at 48h no significant regulation upon doxorubicin was seen for cdk1, Myt1, phosphorylated Myt1, phosphorylated Wee1 and phosphorylated cdc25 whereas phosphorylated cdk1 and p21 were also increased (data not shown).
Influence of cathepsin B suppression on cell cycle phases and overall cell viability
Since as described above doxorubicin treatment caused changes in some of the investigated cell cycle regulatory proteins, we next investigated whether this translates in alteration regarding cell cycle phases. As shown in Figure 6A (Fig. 6A right) . to 51±2.4% (doxorubicin+CA074Me) whereas in cathepsin B suppressed cells no additional effects of CA074Me were oberserved (70±5.8% for doxorubicin alone and 65±22.2% for doxorubicin+CA074Me, Figure 6C ).
Impact of cathepsin B expression on cytotoxicity of doxorubicin in different tumor cell lines
To test whether cathepsin B expression is important for cytotoxic response to doxorubicin in in the resistant cell types. Statistical analysis using paired t-tests revealed no significant differences. This implies that acquired resistance to doxorubicin seems not to be based on a reduced cathepsin B expression.
Discussion
Despite its widespread clinical use the mechanism underlying doxorubicin-triggered apoptosis is not completely characterized. Extrinsic, death receptor mediated as well as intrinsic, mitochondria controlled apoptosis contribute to doxorubicin`s mode of action [27;28] .
Activation of caspases seems not to be mandatory for cell death upon doxorubicin [16] [17] [18] suggesting the presence of additional factors. In the last decade numerous reports highlight the potential role of cathepsin B in controlling apoptosis but its role in drug induced apoptosis has not been addressed in a systematic manner. Using non specific pharmacological inhibitors evidence pointed to an involvement in cell death induced by Bortezomib, paclitaxel and camptothecin [8;9] . Previous experiments indicated selective up-regulation of cathepsin B by doxorubicin but not by other anticancer drugs tested [11] . Growing evidence supports the participation of mitochondrial dysfunction in cathepsin Bmediated apoptosis [10;32] . In our model, cathepsin B suppressed cells showed a significantly lesser decline of intact mitochondrial membrane potential after 56 to 96h of doxorubicin application. Therefore, the preventing effect of cathepsin B knockdown on loss of mitochondrial membrane potential is apparent after up-regulation of cathepsin B [11] .
Interestingly, treatment with the Caspase 3 inhibitor Z-DEVD-fmk also resulted in reduced loss of mitochondrial permeability suggesting that Caspase 3 signals a mitochondrial amplification loop as shown in Granzyme B mediated apoptosis [33] .
It was found that cathepsin B attacks mitochondria through processing of Bid [34] . Bid cleavage, however, could not be detected following doxorubicin whereas the full-length form of Bid was strongly present in untreated and doxorubicin-treated control transfected as well as in cathepsin B suppressed cells. These data suggest a minor role of Bid cleavage in doxorubicin-induced apoptosis in our model confirming that cathepsins are still able to promote apoptosis even in the absence of Bid processing [35] .
Mitochondrial permeabilization causes release of AIF and cytochrome C from mitochondrial interspace to the cytosol [16] . In TNF-treated hepatocytes cathepsin B enhances mitochondrial release of cytochrome C [32] and cathepsin B silencing in HeLa cells blocks granulysin-mediated release of cytochrome C and AIF [36] . For both cytochrome C and AIF a strongly reduced release into cytosol was seen in our cathepsin B silenced cells. For AIF a caspase-independent translocation from mitochondria to the nucleus inducing nuclear apoptosis through chromatin condensation and DNA fragmentation was demonstrated [37] .
Both chromatin condensation and DNA fragmentation are known to be a consequence of doxorubicin treatment in tumor cells [38] suggesting that AIF could be a potential mediator of these processes. Furthermore, in several models AIF can trigger the release of cytochrome C from mitochondria [39] and could therefore compensate the missing function of truncated BID in our model.
Permeabilization of the outer membrane of mitochondria is regulated by proteins of the Bcl-2 family [40] . Bcl-2 and Bcl-X L inhibit apoptosis by preventing mitochondria membrane permeabilization. Doxorubicin-induced apoptosis both in control transfectants as well as in cathepsin B silenced cells translated in a down-regulation of Bcl-2 upon doxorubicin. In contrast to Bcl-2, Bcl-xL was significantly increased upon doxorubicin in both control transfectants as well as cathepsin B suppressed cells which could act as compensatory factor for Bcl-2 down-regulation.
To clarify whether suppression of cathepsin B has any impact on the cell cycle, we investigated whether a differential modulation of cell cycle regulators upon doxorubicin occurred. Phosphorylation and thereby inactivation of cdk1 (cyclin dependent kinase 1) was significantly stronger in cathepsin B knockdown cells. Cdk1 inactivation has been reported to decrease the fraction of cells entering apoptosis [41] which is in agreement with our finding of a reduced subG 1 fraction in the cathepsin B silenced cells.
Phosphorylation of cdk1 is carried out by Wee1 and Myt1 kinases which are also inhibited by phosphorylation [25] . Additionally, the inhibitory phosphorylation of cdk1 is removed by the cdc25 protein phosphatase [25] but upon doxorubicin activity of cdc25 was not changed.
Concerning Myt1 and Wee1 phosphorylation, there was an unchanged level of active protein.
Thus, doxorubicin leads to inhibition of cdk1 through phosphorylation but this seems not to be influenced by Wee1, Myt1 or cdc25.
During the cell cycle, cdk1 is regulated in part by the cyclin-dependent kinase inhibitor p21 [26] . Expression of p21, which negatively regulates cdk activity and mediates growth arrest in the G 2 phase [42] , was up-regulated without induction of p53 expression as already shown [43] . Interestingly, at 72h the doxorubicin-mediated increase of p21 was significantly stronger in control transfectants than in cathepsin B knockdown cells. An elevated protein level of p21 upon doxorubicin was already shown for senescent cells [44] but preliminary experiments in our HeLa model by using a clonogenic assay showed that both control transfected as well as cathepsin B silenced cells lost the ability to form colonies in a similar matter at a doxorubicin concentration of 1 µM precluding cathepsin B as important determinant in senescence and clonogenicity in our cell model. The senescent phenotype distinguishes cells that survived drug exposure but lost their capacity to divide from those that recover and proliferate further. A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 64 65 ?
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